COVID-19 Vaccine Injury Compensation Program: Lessons Learned From a Review of 10 Implementing Countries

• Published in: Journal of Korean medical science Vol. 39; no. 13; p. e121
• Main Authors: Kang, Cho Ryok, Choe, Young June, Yoon, Seok-Jun
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Academy of Medical Sciences 08.04.2024
• Subjects: Compensation and Redress; COVID-19 - etiology; COVID-19 - prevention & control; COVID-19 Vaccines - adverse effects; Humans; Pandemics - prevention & control; Review; Vaccination - adverse effects; Vaccines - adverse effects; COVID-19; Vaccines; Compensation; Vaccination
• ISSN: 1011-8934; 1598-6357
• DOI: 10.3346/jkms.2024.39.e121

National vaccine injury compensation serves as a crucial and significant safety net for individuals affected by government-recommended vaccines during a pandemic, contributing to the community's overall safety. In the Republic of Korea, compensation for adverse events resulting from coronavirus disease 2019 (COVID-19) vaccinations has been provided through the National Vaccine Injury Compensation Program introduced in 1995. However, there have been limitations with these measures during the COVID-19 pandemic owing to strict criteria for substantiating causality between the vaccine and injury, its nontransparent process of determining whether to compensate, and the compensation amount that is not practically calculated. This article reviewed the Vaccine Injury Compensation Programs in 10 major countries to present implications for improving the Korean system. Expanding the scope of national accountability is essential to compensate for the consequences of adhering to national policies during public health crises. Therefore, valuable insight can be obtained from examining the systems in Germany, Japan, and Taiwan, which have implemented more relaxed criteria for determining causality in compensation cases; Thailand's system, which provides the mandatory payment of preliminary compensation for damage caused by vaccination; systems in Germany, France, and Japan, which offer compensation for vaccine injuries from a practical perspective; and systems in France and the United Kingdom, which have a process allowing the assessment records to be shared with the claimants. Furthermore, a dedicated agency for vaccine injury compensation, as seen in France, the United Kingdom, and Australia, is necessary to enhance the efficiency of the Korean system.